Skip to main content

Table 1 Patient characteristics and comparison of tumor uptake of fludeoxyglucose/18F-fluoromisonidazole

From: Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer

     FDG-SUVmax FMISO-TBR
Variables   Number (%) Mean SD p Value Mean SD p Value
Number of patients   44        
Age, years Average 53.5        
(range) (38–78)        
< 50 20 (45.4) 11.1 4.4 0.02 1.3 0.4 0.3
≥ 50 24 (45.5) 7.9 4.2 1.2 0.4
Tumor size Average 40.9        
(range) (14–80)        
< 4 cm 25 (56.8) 8 3.6 0.02 1.1 0.4 0.03
≥ 4 cm 19 (43.1) 11.1 5.1 1.4 0.4
Histology IDC 41 (93.1) 9.6 4.4 0.1 1.2 0.4 0.9
Others 3 (6.8) 6 3.5 1.2 0.7
Nuclear grade 1/2 17 (38.6) 7.4 3.6 0.06 1 0.2 0.007
3 21 (47.7) 10 4.7 1.4 0.5
Unknown 6 (13.6)    
Nodal involvement 0 12 (27.2) 6.8 3.3 0.01 1.2 0.4 0.9
≥ 1 32 (72.7) 10.5 4.6 1.2 0.4
ER + 26 (59) 9.1 4.2 0.7 1.1 0.3 0.04
18 (40.9) 9.6 5.1 1.4 0.5
PgR + 19 (43.1) 7.9 3.1 0.07 1 0.2 0.009
25 (56.8) 10.4 5.2 1.4 0.5
HER2 + 7 (15.9) 7.8 3.6 0.3 1.2 0.2 1
37 (84) 9.6 4.7 1.2 0.4
Luminal A   7 (15.9) 7.8 2.5 0.4 0.9 0.2 0.03
Luminal B   16 (36.4) 9.7 4.8 1.1 0.3
TNBC   14 (31.8) 10.5 5.4 1.4 0.5
HER2   7 (15.9) 7.9 3.6 1.2 0.2
Chemotherapy + 39 (88.6) 9.7 4.6 0.1 1.2 0.4 0.01
5 (11.4) 6.4 3 0.7 0.1
Endocrine therapy + 26 (59) 9.1 4.2 0.7 1.1 0.3 0.04
18 (40.9) 9.6 5.1 1.4 0.5
  1. Abbreviations: FDG 18F-fluorodeoxyglucose, FMISO 18F-fluoromisonidazole, IDC Invasive ductal carcinoma, ER Estrogen receptor, PgR Progesterone receptor, TBR Tissue-to-blood ratio, TNBC Triple-negative breast cancer, HER2 Human epidermal growth factor receptor 2, SUVmax Maximum standardized uptake value